Agomab Therapeutics (Series D)
Funding Details
- Awarder
- Inbox
- Date Award
- October 25, 2024
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $89,000,000
Company Info
- Traction
- Agomab has reported positive data from Phase I trials of AGMB-129 and is currently conducting a Phase IIa trial with interim results expected in early 2025.
- Organizations Involved
- Sanofi, Invus
- Company Description
- Agomab Therapeutics is focused on developing treatments for fibrotic diseases, including its lead candidate AGMB-129 for fibrostenosing Crohn’s disease. The company is advancing its candidates through clinical trials with significant funding support.
- Market
- Fibrotic diseases
- Location
- Belgium
- Coinvestors
- Sanofi, Invus